JP2005510203A - Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法 - Google Patents

Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法 Download PDF

Info

Publication number
JP2005510203A
JP2005510203A JP2002582209A JP2002582209A JP2005510203A JP 2005510203 A JP2005510203 A JP 2005510203A JP 2002582209 A JP2002582209 A JP 2002582209A JP 2002582209 A JP2002582209 A JP 2002582209A JP 2005510203 A JP2005510203 A JP 2005510203A
Authority
JP
Japan
Prior art keywords
seq
acid sequence
nucleic acid
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002582209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005510203A6 (ja
JP2005510203A5 (https=
Inventor
ジェームズ ジー． メッツ
ウィリアム アール． バルクレイ
ジェームズ エイチ． フラッテ
ジェリー エム． クナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Martek Biosciences Boulder Corp
Original Assignee
Martek Biosciences Boulder Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Boulder Corp filed Critical Martek Biosciences Boulder Corp
Publication of JP2005510203A publication Critical patent/JP2005510203A/ja
Publication of JP2005510203A6 publication Critical patent/JP2005510203A6/ja
Publication of JP2005510203A5 publication Critical patent/JP2005510203A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8273—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for drought, cold, salt resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C12P7/625—Polyesters of hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6434—Docosahexenoic acids [DHA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
JP2002582209A 2001-04-16 2002-04-16 Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法 Withdrawn JP2005510203A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US28406601P 2001-04-16 2001-04-16
US60/284,066 2001-04-16
US29879601P 2001-06-15 2001-06-15
US60/298,796 2001-06-15
US32326901P 2001-09-18 2001-09-18
US60/323,269 2001-09-18
PCT/US2002/012254 WO2002083870A2 (en) 2001-04-16 2002-04-16 Pufa polyketide synthase systems and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008156666A Division JP4781399B2 (ja) 2001-04-16 2008-06-16 Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2005510203A true JP2005510203A (ja) 2005-04-21
JP2005510203A6 JP2005510203A6 (ja) 2005-08-04
JP2005510203A5 JP2005510203A5 (https=) 2005-12-22

Family

ID=27403446

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2002582209A Withdrawn JP2005510203A (ja) 2001-04-16 2002-04-16 Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法
JP2008156666A Expired - Lifetime JP4781399B2 (ja) 2001-04-16 2008-06-16 Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法
JP2009239439A Expired - Lifetime JP5460232B2 (ja) 2001-04-16 2009-10-16 Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法
JP2013143216A Expired - Lifetime JP5806259B2 (ja) 2001-04-16 2013-07-09 Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2008156666A Expired - Lifetime JP4781399B2 (ja) 2001-04-16 2008-06-16 Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法
JP2009239439A Expired - Lifetime JP5460232B2 (ja) 2001-04-16 2009-10-16 Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法
JP2013143216A Expired - Lifetime JP5806259B2 (ja) 2001-04-16 2013-07-09 Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法

Country Status (9)

Country Link
EP (5) EP2366773B1 (https=)
JP (4) JP2005510203A (https=)
CN (2) CN101892249A (https=)
AR (1) AR040622A1 (https=)
AU (2) AU2002303394B2 (https=)
CA (1) CA2444164C (https=)
ES (3) ES2567305T3 (https=)
TW (3) TWI426126B (https=)
WO (1) WO2002083870A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527244A (ja) * 2007-05-16 2010-08-12 マーテック バイオサイエンシーズ コーポレーション キメラｐｕｆａポリケチドシンターゼシステムおよびその使用
JP2014195460A (ja) * 2006-08-29 2014-10-16 ディーエスエム アイピー アセッツ ビー．ブイ． 乳幼児用調合乳におけるＤＰＡ（ｎ−６）油の使用
JP2017213008A (ja) * 2009-03-19 2017-12-07 ディーエスエム アイピー アセッツ ビー．ブイ． 多価不飽和脂肪酸シンターゼの核酸分子およびポリペプチド、組成物、ならびにそれらの作製方法および使用
WO2021079975A1 (ja) * 2019-10-23 2021-04-29 ソニー株式会社 表示システム、表示装置、表示方法、及び、移動装置

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US6566583B1 (en) 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
US7211418B2 (en) 1999-01-14 2007-05-01 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US7217856B2 (en) 1999-01-14 2007-05-15 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US7247461B2 (en) 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
EP2960325B1 (en) 2000-01-28 2017-09-27 DSM IP Assets B.V. Enhanced production of lipids containing polyenoic fatty acids by high density cultures of eukaryotic microbes in fermentors
CA2509227C (en) * 2002-12-19 2013-05-21 Monsanto Technology, Llc Elevation of oil levels in brassica plants
KR101234199B1 (ko) * 2003-03-26 2013-02-20 마텍 바이오싸이언스스 코포레이션 Ｐｕｆａ 폴리케타이드 신타제 시스템 및 이의 용도
AU2005214874B2 (en) * 2004-02-13 2010-02-18 Martek Biosciences Corporation Schizochytrium fatty acid synthase (FAS) and products and methods related thereto
DE102004017369A1 (de) * 2004-04-08 2005-11-03 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Screeningverfahren zur Identifizierung von PUFA-PKS in Proben
DE102004017370A1 (de) * 2004-04-08 2005-10-27 Nutrinova Nutrition Specialties & Food Ingredients Gmbh PUFA-PKS Gene aus Ulkenia
CA3056110C (en) 2004-04-22 2020-07-14 Surinder Pal Singh Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
DK1756280T3 (en) 2004-04-22 2015-02-02 Commw Scient Ind Res Org SYNTHESIS OF CHAIN, polyunsaturated fatty acids BY RECOMBINANT CELLS
WO2006135866A2 (en) * 2005-06-10 2006-12-21 Martek Biosciences Corporation Pufa polyketide synthase systems and uses thereof
AU2006265801B2 (en) 2005-07-01 2011-07-14 Martek Biosciences Corporation Polyunsaturated fatty acid-containing oil product and uses and production thereof
KR101524398B1 (ko) 2006-03-15 2015-06-04 디에스엠 아이피 어셋츠 비.브이. Ｐｕｆａ 폴리케티드 신타제 시스템을 이용한 이종 생물체내 다불포화 지방산의 제조
CN101578363A (zh) 2006-08-29 2009-11-11 联邦科学技术研究组织 脂肪酸的合成
NO2358882T3 (https=) 2008-11-18 2017-12-23
PL2861059T3 (pl) 2012-06-15 2017-10-31 Commw Scient Ind Res Org Wytwarzanie długołańcuchowych wielonienasyconych kwasów tłuszczowych w komórkach roślinnych
NZ721036A (en) 2013-12-18 2023-07-28 Grains Res & Dev Corp Lipid comprising long chain polyunsaturated fatty acids
PH12016502586B1 (en) 2014-06-27 2023-07-19 Commw Scient Ind Res Org Lipid comprising docosapentaenoic acid
US12241101B2 (en) 2018-08-10 2025-03-04 Kyowa Hakko Bio Co., Ltd. Microorganism producing polyunsaturated fatty acid and method for producing polyunsaturated fatty acid
US11613728B2 (en) 2018-08-10 2023-03-28 Kyowa Hakko Bio Co., Ltd. Microorganism producing eicosapentaenoic acid and method for producing eicosapentaenoic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743546A (en) 1985-02-13 1988-05-10 Biotechnica International, Inc. Controlled gene excision
US5130742A (en) 1986-05-20 1992-07-14 Canon Kabushiki Kaisha Camera having selectable white balance modes
US5130242A (en) * 1988-09-07 1992-07-14 Phycotech, Inc. Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
AU5346296A (en) * 1995-04-17 1996-11-07 Japan As Represented By Director-General Of Agency Of Industrial Science And Technology Novel microorganisms capable of producing highly unsaturated fatty acids and process for producing highly unsaturated fa tty acids by using the microorganisms
BR9809946A (pt) 1997-06-04 2000-08-01 Calgene Llc Produção de ácidos graxos poliinsaturados por expressão de genes de sìntese semelhantes a policetìdeo em plantas
US6566583B1 (en) * 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
JP6257306B2 (ja) 2013-12-18 2018-01-10 キヤノン株式会社 着弾位置測定装置および着弾位置測定方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014195460A (ja) * 2006-08-29 2014-10-16 ディーエスエム アイピー アセッツ ビー．ブイ． 乳幼児用調合乳におけるＤＰＡ（ｎ−６）油の使用
JP2010527244A (ja) * 2007-05-16 2010-08-12 マーテック バイオサイエンシーズ コーポレーション キメラｐｕｆａポリケチドシンターゼシステムおよびその使用
JP2017213008A (ja) * 2009-03-19 2017-12-07 ディーエスエム アイピー アセッツ ビー．ブイ． 多価不飽和脂肪酸シンターゼの核酸分子およびポリペプチド、組成物、ならびにそれらの作製方法および使用
WO2021079975A1 (ja) * 2019-10-23 2021-04-29 ソニー株式会社 表示システム、表示装置、表示方法、及び、移動装置

Also Published As

Publication number Publication date
AU2008249168B2 (en) 2012-06-21
ES2567305T3 (es) 2016-04-21
EP2366773A2 (en) 2011-09-21
EP2366774A3 (en) 2012-08-22
JP4781399B2 (ja) 2011-09-28
CN1535312A (zh) 2004-10-06
JP2013255497A (ja) 2013-12-26
EP2366771A2 (en) 2011-09-21
EP2366774A2 (en) 2011-09-21
WO2002083870A2 (en) 2002-10-24
TWI426126B (zh) 2014-02-11
TW201132758A (en) 2011-10-01
TWI337619B (en) 2011-02-21
WO2002083870A3 (en) 2003-03-27
EP2366773A3 (en) 2012-09-05
ES2628553T3 (es) 2017-08-03
JP2010051317A (ja) 2010-03-11
TWI426127B (zh) 2014-02-11
JP2009005700A (ja) 2009-01-15
JP5806259B2 (ja) 2015-11-10
EP1385934A4 (en) 2006-04-26
CN101892249A (zh) 2010-11-24
EP1385934B1 (en) 2015-12-09
JP5460232B2 (ja) 2014-04-02
EP2366772B1 (en) 2016-01-13
EP1385934A2 (en) 2004-02-04
EP2366771A3 (en) 2012-08-22
ES2562766T3 (es) 2016-03-08
AR040622A1 (es) 2005-04-13
TW201040263A (en) 2010-11-16
CA2444164A1 (en) 2002-10-24
AU2002303394B2 (en) 2008-08-21
EP2366773B1 (en) 2017-03-22
CA2444164C (en) 2014-03-04
EP2366772A3 (en) 2012-08-22
AU2008249168A1 (en) 2008-12-11
EP2366772A2 (en) 2011-09-21

Similar Documents

Publication Publication Date Title
JP5806259B2 (ja) Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法
US7960524B2 (en) PUFA polyketide synthase systems and uses thereof
JP2005510203A6 (ja) Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法
AU2002303394A1 (en) PUFA polyketide synthase systems and uses thereof
AU2012227225A1 (en) Pufa polyketide synthase system and uses thereof
HK1162575A (en) Pufa polyketide synthase systems and uses thereof
HK1162578A (en) Pufa polyketide synthase systems and uses thereof
HK1162576A (en) Pufa polyketide synthase systems and uses thereof
HK1162577A (en) Pufa polyketide synthase systems and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080311

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080410

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080512

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080519

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091007

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091102

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110823

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110829

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120904